發(fā)布時(shí)間：2020-12-21 06:56

　　本研究旨在評(píng)估福建省藥品聯(lián)合限價(jià)陽光采購政策對藥品價(jià)格、用量、醫(yī)保費(fèi)用和患者負(fù)擔(dān)的長期影響。對2012.1-2018.8期間產(chǎn)生的59 968條醫(yī)保報(bào)銷數(shù)據(jù)進(jìn)行收集匯總,處理形成月度數(shù)據(jù)后通過間斷時(shí)間序列（ITS）回歸模型進(jìn)行分析�；貧w結(jié)果顯示,該政策執(zhí)行后,（1）競爭性藥品價(jià)格顯著上升,升幅達(dá)128.9%（P<0.01）;非競爭性藥品價(jià)格顯著下降,降幅為18.9%（P<0.01）。（2）樣本藥品用藥頻度顯著下降,降幅達(dá)32.3%（P<0.01）;其中競爭性藥品用藥頻度顯著下降,降幅達(dá)45.9%（P<0.01）;非競爭性藥品用藥頻度卻顯著上升,升幅達(dá)19.1%（P<0.01）。（3）樣本藥品每人次月度總醫(yī)保費(fèi)用沒有顯著變化。（4）患者負(fù)擔(dān)總體沒有顯著變化,但競爭性藥品的自付費(fèi)用顯著上升,升幅達(dá)81.4%（P<0.01）。 

【文章來源】：Journal of Chinese Pharmaceutical Sciences. 2020年02期

【文章頁數(shù)】：14 頁

【文章目錄】：
1. Introduction
2. Data and methods
3. Results
    3.1. Impact on drug price
    3.2. Impact on drug prescription volume
        3.2.1. Impact on all sample drugs
        3.2.2. Impact on competitive sample drugs
        3.2.3. Impact on non-competitive sample drugs
    3.3. Impact on medical insurance expense
        3.3.1. Impact on all sample drugs
        3.3.2. Impact on competitive sample drugs
        3.3.3. Impact on non-competitive sample drugs
    3.4. Impact on patient’s burden
        3.4.1. Impact on all sample drugs
        3.4.2. Impact on competitive sample drugs
        3.4.3. Impact on non-competitive sample drugs
4. Discussion
    4.1. Fujian’s DPUPC policy narrows the price gap between branded drugs and generic drugs
    4.2. Fujian’s DPUPC policy fails to promote generic substitution
    4.3. The effects on medical insurance expense control are influenced by various factors
    4.4. Pay more attention to the increased patient’s burden caused by low PRCR
5. Conclusions


【參考文獻(xiàn)】：
期刊論文
[1]三明市藥品限價(jià)采購政策效果研究（英文）[J]. 尹婷,江濱.  Journal of Chinese Pharmaceutical Sciences. 2018(11)
[2]中國藥品醫(yī)保支付標(biāo)準(zhǔn)政策框架及地方實(shí)踐研究（英文）[J]. 于嘉軒,闕夢圓,王帥,尹婷,汪劍鋒,楊松,江濱.  Journal of Chinese Pharmaceutical Sciences. 2017(05)
[3]用DDDs分析2007年我院抗生素應(yīng)用[J]. 易紅,肖朝暉,袁浩宇.  現(xiàn)代預(yù)防醫(yī)學(xué). 2009(06)



本文編號(hào)：2929405